Bringing Flow Cytometry Capabilities to the Nanoscale

Nano-Flow cytometry allows the direct, single-particle measurement of nano-sized entities such as extracellular vesicles, virus, mitochondria and liposomes for size, concentration by light scatter and markers by fluorescence.

NanoAnalyzer Range

team_img
  • Single laser (488nm blue or 532nm green)
  • One side-scatter channel
  • Two fluorescence channels
  • up to 12,000 particles/min
  • Lower detection limit 7nm (gold nanoparticles) to 40nm (exosomes, viruses)
  • High detection limit (1micron)

Comprehensive Bio-Nanoparticle Analysis

For many years scientists yearned for the possibility of performing flow cytometry to analyse small bio-nanoparticles that are too small to be measured by conventional and high sensitivity instruments. These entities, extracellular vesicles, gene therapy vectors, viruses and drug delivery particles, are promised to become the next generation of therapeutics, but they have been hard to handle and characterise due to their small size and biological or chemical heterogeneity. There is therefore a strong case for bringing flow cytometry capability to the sub-200nm scale.

Innovation brings the solution

NanoFCM has developed the NanoAnalyzer platform that now enables true flow-cytometry measurement at the sub-micron scale, and down to particle sizes unreachable by any other flow cytometers (10-40nm depending on the nature of the substrate). Nano-flow cytometry, the technology that underpins the NanoAnalyzer, removes bias and uncertainty stemming from the use of fluorescence signal triggering by using its highly sensitive side-scatter channel to trigger particle events. The single-particle nature of the measurement prevents uncontrolled swarming events, reinforcing data integrity. High resolution of both scatter and fluorescence channels allows the assessment of subpopulations, based on size or on bio-chemical properties.

A new paradigm for bio-nanoparticle analysis

Nano-flow cytometry’s ability to measure simultaneously a (bio)-nanoparticle population for size, size distribution and bio-chemical properties on a single instrument dramatically improves data quality and throughput compared to the traditional, multiple-techniques approach involving particle characterisation and counting (DLS, NTA, RPS), combined with chemical and biological function assessment (ELISA, Western Blot, Flow Cytometry, PCR). Quantitative measurement of the active and contaminant particles in a single preparation opens up the possibility of characterisation-based nanomedicine regulatory approval, and allows the conduct of large-scale clinical studies. From the research laboratory to the quality control department, NanoFCM delivers comprehensive bio-nano analysis.

Read More

Latest News

ISEV-MRS joint conference on Extracellular Vesicles in Cancer

ISEV-MRS joint conference on Extracellular Vesicles in Cancer

May 2019

NanoFCM will take part to the first ISEV-MRS joint conference as a silver sponsor.

Read More
CYTO 2019

CYTO 2019

May 2019

NanoFCM will participate to the CYTO 2019 Congress in Vancouver, Canada, 22-26th June.

Read More
Nottingham Centre of Excellence

Nottingham Centre of Excellence

April 2019

Nottingham – NanoFCM Co., Ltd. today announced that it has established a new facility to support existing and potential users of its Nano-Flow Cytometry platform.

Read More